Table 2

 Current status of prognostic biomarkers in Barrett’s oesophagus

BiomarkerPhase 1/2Phase 3Phase 4Phase 5/6Ready for clinical use?Comments
LOH, loss of heterozygosity.
DysplasiaXDiagnostic but poorly prognosticIdeally two or more specialist pathologists. Current gold standard but poor reproducibility;
P53XNoSingle phase 4 study showing 17p LOH is a good marker of progression
P16XXXNoHypothetically good but lacks scientific data
AneuploidyXXNoDifficult technique to reproduce
Cyclin D1XXNoPossible role in combination with p16
Ki-67XXXNoSingle phase 4 trial found no evidence that S phase was a predictor of MCS progression